All In Biotech

Drug Trial Radar · NCT06197672

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 19, 2024

Primary completion

Dec 2027

Study completion Dec 2042

Sponsor

Lead sponsor
Huda SalmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
iCell Gene Therapeutics
First posted
Jan 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory AML. The study will evaluate safety in this subject population and also the presence of efficacy signal described by elimination of residual disease to qualify subjects for stem cell transplant.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • CD4CARBiological

    CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Dose finding: Maximum tolerated dose (MTD) is defined as one dose level lower than the Dose Limiting Toxicity (DLT) of the CD4CAR in AML. Optimal dose is highest safe dose that produces the most response.Time frame: Day 0 through Day 28 post-infusion
  2. Persistence and biologic behavior of CD4CAR as measured by a. Serial blood and marrow sampling to detect CD4CAR over time post infusion. b. Serial testing for CD4CAR proliferation, differentiation and polarization if feasible overtime after infusion.Time frame: Day 0 Through Day28 post infusion
  3. 3. Determine the influence of CD4CAR on T regsTime frame: Day 0 through Day 28
  4. Determine the influence of CD4CAR on myeloiod derived suppressor cells, MDSCsTime frame: Day 0 through Day 28

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • Riley Hospital for Children

    Indianapolis, Indiana

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.